Combining IDA’s expert medical and scientific insights with the M3 Group’s health care provider network and large scale clinical research platform, IDA can provide comprehensive support of commercialization planning and implementation. Furthermore, in select cases, IDA and the M3 Group can engage in creative risk-sharing partnering approaches that can help to accelerate product launch and enhance product value in Japan and Asia.

A) Commercialization Services

  • Commercial Launch Preparation- IDA can prepare medical communications materials based on an expert scientific understanding of products and then validate the effectiveness of messaging through surveying M3’s healthcare provider network
  • Medical and Product Communications- Using “MR-kun” M3 consistently and repeatedly delivers product and disease information directly to doctors in a targeted fashion and receives and responds to questions and feedback from doctors to ensure their full and accurate  understanding of product positioning
  • Post-Marketing Evidence Generation- Leveraging M3’s extensive capabilities, IDA provides expert design, planning and conduct of large scale post-marketing clinical trials to  generate post-marketing evidence of product efficacy and safety which provides for continual enhancement of product value after initial launch

B) Partnering Support and Risk-Sharing Development

Many of IDA’s clients are pursuing the partnering of their products in Japan with either domestic Japanese or global pharmaceutical companies.  IDA can support obtaining value-added licensing deals through partnering support services risk-sharing development arrangements

 

Partnering Support Services

  • Identifying potential partners thru a disciplined screening process based on mutually defined criteria
  • Support communicating the value of products as well as the strategy behind the global and Japanese development plan to potential partners with a multi-disciplinary team of experts who are bilingual and bicultural
  • Support the detailed negotiation process with selected partners

 

Risk-Sharing Development

Furthermore, many clients pursuing partnering understandably wish to avoid significant investment in Japanese development activities prior to out-licensing. However, this approach requires executing deals before products can be de-risked at a lower value. One solution offered by IDA is to, on a case-by-case basis depending on product profile, conduct part or all of IDA’s services at risk in exchange for sharing in the increased deal value resulting from achievement of key Japanese development milestones.

© 2016 IDA Integrated Development Associates.